$0.3872
0.02717.53%
Last update: Nov 12, 4:19 PM
Ensysce Biosciences Inc
ENSCNASDAQ
Ensysce Biosciences fell 81.2% from $2.06 to $0.39, behind the S&P 500's +11.2%. Its worst day was Feb 10 (−27.5%), and its low came Jul 28 at $0.25.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.29 missed the $-0.90 estimate on $493,104.00 revenue (est. $1.4M).
−4.9% · S&P 500 −0.9%
Ensysce Biosciences shares rose 31.8%, while the S&P 500 rose 0.5%.
Story events cover the past 12 months · Times ET
+31.8% · S&P 500 +0.5%
Ensysce Biosciences stock surged 58% after launching a strategic review to explore partnerships, licensing deals, or asset sales.
+57.8%, the year's best day · S&P 500 −0.5%
Ensysce Biosciences shares rose 32.9%, while the S&P 500 fell 1.4%.
+32.9% · S&P 500 −1.4%
EPS of $-0.75 beat the $-1.26 estimate on $1.9M revenue (est. $500,000.00).
+4.8% · S&P 500 +2.9%
EPS of $-0.52 beat the $-0.73 estimate on $960,999.00 revenue (est. $1.9M).
+13.2% · S&P 500 −0.1%
Ensysce Biosciences closed at its lowest level of the year, 87.8% below where the year started.
−4.1% · S&P 500 +0.2%
Acquisition includes clinical-stage neuroplastogenic therapy with U.S.
+44.8%, on 498M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.20 beat the $-0.50 estimate on $1.2M revenue (est. $994,000.00).
+14.7% · S&P 500 −0.2%
Where it ended: a close of $0.39 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.13, revenue est. $1.2M).
Nothing in the past 12 months.
All ENSC dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ENSC and SPY from Benzinga historical bars. Not investment advice.
